Credit Suisse AG lifted its holdings in Waters Co. (NYSE:WAT) by 22.5% during the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 111,215 shares of the medical instruments supplier’s stock after buying an additional 20,447 shares during the period. Credit Suisse AG owned approximately 0.15% of Waters worth $21,652,000 as of its most recent filing with the Securities and Exchange Commission.
Several other large investors have also bought and sold shares of WAT. Alps Advisors Inc. acquired a new stake in Waters during the 2nd quarter worth approximately $478,000. Raymond James Financial Services Advisors Inc. lifted its holdings in Waters by 5.8% during the 2nd quarter. Raymond James Financial Services Advisors Inc. now owns 7,118 shares of the medical instruments supplier’s stock worth $1,378,000 after purchasing an additional 391 shares during the last quarter. TD Asset Management Inc. lifted its holdings in Waters by 74.0% during the 2nd quarter. TD Asset Management Inc. now owns 43,526 shares of the medical instruments supplier’s stock worth $8,427,000 after purchasing an additional 18,509 shares during the last quarter. Sumitomo Mitsui Trust Holdings Inc. lifted its holdings in Waters by 5.4% during the 2nd quarter. Sumitomo Mitsui Trust Holdings Inc. now owns 244,477 shares of the medical instruments supplier’s stock worth $47,328,000 after purchasing an additional 12,497 shares during the last quarter. Finally, Smith Asset Management Group LP lifted its holdings in Waters by 18.2% during the 2nd quarter. Smith Asset Management Group LP now owns 164,388 shares of the medical instruments supplier’s stock worth $31,864,000 after purchasing an additional 25,303 shares during the last quarter. 99.26% of the stock is currently owned by hedge funds and other institutional investors.
In other news, Director Christopher A. Kuebler sold 8,000 shares of Waters stock in a transaction on Friday, November 16th. The stock was sold at an average price of $199.67, for a total value of $1,597,360.00. Following the transaction, the director now owns 18,911 shares in the company, valued at approximately $3,775,959.37. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Also, Director Thomas P. Salice sold 3,500 shares of Waters stock in a transaction on Wednesday, October 31st. The shares were sold at an average price of $192.00, for a total value of $672,000.00. Following the completion of the transaction, the director now owns 20,911 shares in the company, valued at approximately $4,014,912. The disclosure for this sale can be found here. 0.98% of the stock is owned by company insiders.
Waters stock opened at $198.58 on Monday. Waters Co. has a one year low of $167.93 and a one year high of $220.20. The company has a debt-to-equity ratio of 0.61, a quick ratio of 5.93 and a current ratio of 6.63. The firm has a market cap of $15.04 billion, a price-to-earnings ratio of 26.51, a P/E/G ratio of 2.38 and a beta of 0.94.
Waters (NYSE:WAT) last posted its quarterly earnings data on Tuesday, October 23rd. The medical instruments supplier reported $1.92 EPS for the quarter, topping the Zacks’ consensus estimate of $1.90 by $0.02. Waters had a return on equity of 30.68% and a net margin of 2.32%. The firm had revenue of $578.02 million for the quarter, compared to analyst estimates of $587.43 million. During the same quarter last year, the company earned $1.77 EPS. The company’s revenue was up 2.2% on a year-over-year basis. Equities research analysts expect that Waters Co. will post 8.05 earnings per share for the current fiscal year.
WAT has been the subject of several research reports. Zacks Investment Research raised Waters from a “sell” rating to a “hold” rating in a report on Friday, August 17th. Leerink Swann cut Waters from an “outperform” rating to a “market perform” rating in a report on Monday, October 8th. UBS Group initiated coverage on Waters in a report on Tuesday, October 9th. They set a “neutral” rating and a $210.00 price target for the company. Morgan Stanley lifted their price target on Waters from $204.00 to $211.00 and gave the stock an “equal weight” rating in a report on Wednesday, October 10th. Finally, Cleveland Research raised Waters from a “sell” rating to a “neutral” rating in a report on Thursday, October 11th. Three equities research analysts have rated the stock with a sell rating, eleven have issued a hold rating and four have assigned a buy rating to the company. The stock presently has an average rating of “Hold” and a consensus price target of $205.07.
ILLEGAL ACTIVITY NOTICE: “Credit Suisse AG Boosts Stake in Waters Co. (WAT)” was originally reported by American Banking News and is the sole property of of American Banking News. If you are reading this story on another website, it was stolen and republished in violation of US and international trademark and copyright laws. The correct version of this story can be read at https://www.americanbankingnews.com/2018/12/03/credit-suisse-ag-boosts-stake-in-waters-co-wat.html.
Waters Corporation, a specialty measurement company, provides analytical workflow solutions in the United States, Europe, Asia, and internationally. It designs, manufactures, sells, and services high and ultra performance liquid chromatography technology, as well as mass spectrometry (MS) technology systems and support products, including chromatography columns, other consumable products, and post-warranty service plans.
Further Reading: How the Consumer Price Index (CPI) is calculated?
Want to see what other hedge funds are holding WAT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Waters Co. (NYSE:WAT).
Receive News & Ratings for Waters Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Waters and related companies with MarketBeat.com's FREE daily email newsletter.